2008: Pulmonary Pharmacology and Therapeutics Publication: The safety and effects of the beta-blocker, nadolol, in mild asthma

Apr 22, 2008: Dr. Richard Bond featured on Alexander Berardi's CounterThink.TV

Feb 19, 2008: Drug Reduces Airway Mucus in Preclinical Asthma Model

Jan 29, 2008: Inverseon Announces Positive Phase IIa Asthma Study

Inverseon is a clinical-stage company re-profiling drugs for chronic diseases. Inverseon's lead program is INV102, a beta inverse agonist for asthma. The value of this chronic inverse agonist approach is that treatment over time up-regulates the corresponding receptors, resulting in improved therapeutic benefit.

INV102 is an oral, daily therapy which has completed a Phase IIa proof-of-concept human study for asthma. There are over 20 million Americans with asthma and asthma morbidity and mortality continue to increase.